For Investors
Eryvo acquires discarded drug assets at very financially favorable terms. These drugs often reside in companies without resources or the interest in moving them forward. Eryvo leverages its preferred vendor relationships it has established in the CRO universe to develop at substantively lower cost and time.
Eryvo Pharma Solutions, Inc. deploys investor friendly structures:
Public Benefit Corporation
Qualified Small Business Stock (QSBS)
Single or multiple investor backed assets
Eryvo’s drug assets are available via its bespoke operating model
Eryvo investors are one step away from creating value in rare biotech opportunities with an unparalleled, higher than normal probability of success:
A threefold higher return than venture funded drug development companies.
A shorter path to liquidity (<three years) than typical biotech companies funded by traditional VC capital.
An inherently disciplined operating plan.
A small, experienced, focused execution team that leverages its relationships with thought leaders and the rare disease community.
Collectively, with these uncommon assets and distinct strategy, Eryvo’s assets generate an unparalleled benchmark in biotech investing.
Eryvo identifies discarded drugs that hold value in underappreciated development strategies. With investor backing, Eryvo advances drugs with lower science risk and therefore a relatively higher probability of approval.
Three characteristics of Eryvo’s approach are overlooked by investors:
By advancing one catalyst ahead, Eryvo drug assets have a short timeline to approval:
Investments fund one clinical event (<two years) through regulatory review (<three years total).
Most Eryvo assets target a rare disease where a patient organization has identified patients to support a relatively quick enrollment into a small pivotal trial.
Eryvo drug assets carry a high volume of preclinical, Phase 1 and at least Phase 2 with evidence to describe the drugs’ behavior and a “roadmap: to now properly design the next clinical event.
Every clinical trial “makes sense” or it would have not been attempted. But only after the trial in sick patients can the drugs’ mechanism of action + patients’ etiology be paired determine how (if any) clinical trial can be executed with experience.
Eryvo investors underwrite the lower risk of clinical trial execution and underwrite one risk at a time… no compounding risks.
Eryvo drug assets’ cost basis begins near zero… offering a much broader opportunity in selecting an indication with the lowest clinical trial risk.
Collectively, these drive the faster pace and lower risk of Eryvo assets while the lower denominator (development costs) generates a higher return on investor capital. Once an investor is under CDA, Eryvo reviews the risk-reward proposition in greater detail, including a deep dive on the specific steps in developing and selling Eryvo drug assets.
Market is seeing value in late stage assets
